385 related articles for article (PubMed ID: 32793481)
1. Theranostic Pretargeting Drug Delivery and Imaging Platforms in Cancer Precision Medicine.
Hapuarachchige S; Artemov D
Front Oncol; 2020; 10():1131. PubMed ID: 32793481
[TBL] [Abstract][Full Text] [Related]
2. Dual Radionuclide Theranostic Pretargeting.
Keinänen O; Brennan JM; Membreno R; Fung K; Gangangari K; Dayts EJ; Williams CJ; Zeglis BM
Mol Pharm; 2019 Oct; 16(10):4416-4421. PubMed ID: 31483993
[TBL] [Abstract][Full Text] [Related]
3. Pretargeting in nuclear imaging and radionuclide therapy: Improving efficacy of theranostics and nanomedicines.
Stéen EJL; Edem PE; Nørregaard K; Jørgensen JT; Shalgunov V; Kjaer A; Herth MM
Biomaterials; 2018 Oct; 179():209-245. PubMed ID: 30007471
[TBL] [Abstract][Full Text] [Related]
4. PET-MR Guided, Pre-targeted delivery to HER2(+) Breast Cancer Model.
Si G; Hapuarachchige S; Lesniak WG; Artemov D
Res Sq; 2024 Feb; ():. PubMed ID: 38464126
[TBL] [Abstract][Full Text] [Related]
5. Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology.
Gomes Marin JF; Nunes RF; Coutinho AM; Zaniboni EC; Costa LB; Barbosa FG; Queiroz MA; Cerri GG; Buchpiguel CA
Radiographics; 2020 Oct; 40(6):1715-1740. PubMed ID: 33001789
[TBL] [Abstract][Full Text] [Related]
6. Pretargeted imaging and radioimmunotherapy of cancer using antibodies and bioorthogonal chemistry.
van de Watering FC; Rijpkema M; Robillard M; Oyen WJ; Boerman OC
Front Med (Lausanne); 2014; 1():44. PubMed ID: 25593917
[TBL] [Abstract][Full Text] [Related]
7. Advancing cancer theranostics through biomimetics: A comprehensive review.
Anitha K; Chenchula S; Surendran V; Shvetank B; Ravula P; Milan R; Chikatipalli R; R P
Heliyon; 2024 Mar; 10(6):e27692. PubMed ID: 38496894
[TBL] [Abstract][Full Text] [Related]
8. Nano-Theranostics for the Sensing, Imaging and Therapy of Prostate Cancers.
Calatayud DG; Neophytou S; Nicodemou E; Giuffrida SG; Ge H; Pascu SI
Front Chem; 2022; 10():830133. PubMed ID: 35494646
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance imaging-guided and targeted theranostics of colorectal cancer.
Li Y; Xin J; Sun Y; Han T; Zhang H; An F
Cancer Biol Med; 2020 May; 17(2):307-327. PubMed ID: 32587771
[TBL] [Abstract][Full Text] [Related]
10. Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-concept.
Rondon A; Schmitt S; Briat A; Ty N; Maigne L; Quintana M; Membreno R; Zeglis BM; Navarro-Teulon I; Pouget JP; Chezal JM; Miot-Noirault E; Moreau E; Degoul F
Theranostics; 2019; 9(22):6706-6718. PubMed ID: 31588245
[No Abstract] [Full Text] [Related]
11. Copper radiopharmaceuticals for theranostic applications.
Ahmedova A; Todorov B; Burdzhiev N; Goze C
Eur J Med Chem; 2018 Sep; 157():1406-1425. PubMed ID: 30282317
[TBL] [Abstract][Full Text] [Related]
12. Viewing the Emphasis on State-of-the-Art Magnetic Nanoparticles: Synthesis, Physical Properties, and Applications in Cancer Theranostics.
Kaliamurthi S; Demir-Korkmaz A; Selvaraj G; Gokce-Polat E; Wei YK; Almessiere MA; Baykal A; Gu K; Wei DQ
Curr Pharm Des; 2019; 25(13):1505-1523. PubMed ID: 31119998
[TBL] [Abstract][Full Text] [Related]
13. Radiolabeled albumin through S
Fischer NH; Lopes van den Broek SI; Herth MM; Diness F
RSC Adv; 2022 Dec; 12(54):35032-35036. PubMed ID: 36540259
[TBL] [Abstract][Full Text] [Related]
14. Pretargeted Alpha Therapy of Disseminated Cancer Combining Click Chemistry and Astatine-211.
Timperanza C; Jensen H; Bäck T; Lindegren S; Aneheim E
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111352
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Applications of Pretargeting.
Verhoeven M; Seimbille Y; Dalm SU
Pharmaceutics; 2019 Sep; 11(9):. PubMed ID: 31480515
[TBL] [Abstract][Full Text] [Related]
16. Site-specific conjugation allows modulation of click reaction stoichiometry for pretargeted SPECT imaging.
Mandikian D; Rafidi H; Adhikari P; Venkatraman P; Nazarova L; Fung G; Figueroa I; Ferl GZ; Ulufatu S; Ho J; McCaughey C; Lau J; Yu SF; Prabhu S; Sadowsky J; Boswell CA
MAbs; 2018; 10(8):1269-1280. PubMed ID: 30199303
[TBL] [Abstract][Full Text] [Related]
17. Polymer Vesicles: Modular Platforms for Cancer Theranostics.
Wang F; Xiao J; Chen S; Sun H; Yang B; Jiang J; Zhou X; Du J
Adv Mater; 2018 Apr; 30(17):e1705674. PubMed ID: 29450915
[TBL] [Abstract][Full Text] [Related]
18. Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery.
Yang Q; Parker CL; McCallen JD; Lai SK
J Control Release; 2015 Dec; 220(Pt B):715-26. PubMed ID: 26407672
[TBL] [Abstract][Full Text] [Related]
19. Bioorthogonal chemistry: implications for pretargeted nuclear (PET/SPECT) imaging and therapy.
Knight JC; Cornelissen B
Am J Nucl Med Mol Imaging; 2014; 4(2):96-113. PubMed ID: 24753979
[TBL] [Abstract][Full Text] [Related]
20. Advancements in Applications of Surface Modified Nanomaterials for Cancer Theranostics.
Ahmad IZ; Kuddus M; Tabassum H; Ahmad A; Mabood A
Curr Drug Metab; 2017; 18(11):983-999. PubMed ID: 28969548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
